Breaking Finance News

Krystal Biotech (UNKNOWN:KRYS) target price raised to $23.00, released a research note earlier today by Ladenburg Thalmann

Ladenburg Thalmann bumped up the target of Krystal Biotech (UNKNOWN:KRYS) to $23.00 stating a potential upside of 1.11%.

Boasting a price of $10.91, Krystal Biotech (UNKNOWN:KRYS) traded 10.18% higher on the day. With the last stock price close up 6.66% from the two hundred day average, compared with the S&P 500 Index which has increased 0.03% over the date range. Krystal Biotech has recorded a 50-day average of $10.03 and a two hundred day average of $10.03. Volume of trade was up over the average, with 56,602 shares of KRYS changing hands over the typical 55,572

Recent Performance Chart

Krystal Biotech (UNKNOWN:KRYS)

Krystal Biotech has 52 week low of $9.42 and a 52 week high of $11.98 and has a market capitalization of $0.

Brief Synopsis On Krystal Biotech (UNKNOWN:KRYS)

Krystal Biotech, Inc. gene therapy company. The Company is engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. The Company has developed a Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases. The Company's products include KB103 and KB104.The Compnay's KB103 is in preclinical development to treat dystrophic epidermolysis bullosa, or DEB, a rare and severe genetic disease. The Compnay's KB104 is to treat Netherton Syndrome, a severe form of ichthyosis, which is a family of genetic skin disorders associated with thickened scaly skin and characterized by chronic skin inflammation, itchiness, dehydration and stunted growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.